MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

October 31 2017 The medicines regulator has issued four drug safety updates (DRU) relating to...

PPIs may add to liver disease problems in people with alcohol dependency, suggests study

PPIs may add to liver disease problems in people with alcohol dependency, suggests study

October 17 2017 Protein pump inhibitors could supress stomach acid secretion to the extent it...

Pregnant women are not always informed of risks associated with sodium valproate

Pregnant women are not always informed of risks associated with sodium valproate

September 26 2017 Almost a fifth of women with epilepsy (18%) who take sodium valproate are not...

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

September 4 2017 Ibuprofen is associated with increased blood pressure and hypertension compared...

  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:47
  • MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    Tuesday, 31 October 2017 20:03
  • PPIs may add to liver disease problems in people with alcohol dependency, suggests study

    PPIs may add to liver disease problems in people with alcohol dependency, suggests study

    Tuesday, 17 October 2017 14:27
  • Pregnant women are not always informed of risks associated with sodium valproate

    Pregnant women are not always informed of risks associated with sodium valproate

    Tuesday, 26 September 2017 14:14
  • Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Monday, 04 September 2017 15:12

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alcohol imageOctober 17 2017

Protein pump inhibitors could supress stomach acid secretion to the extent it lets intestinal bacteria trigger or worsen liver disease, a new study has proposed.

 The US study has looked at the affect of the PPI omeprazole on the progression of liver disease in rats with alcohol-induced liver disease. Acid suppression was found to be linked to an increase in Enterococcus in the intestine which then migrated to the liver, causing hepatic inflammation, and stimulating any existing liver disease.

In addition, the researchers looked at the association between PPI usage and the development of alcoholic liver disease (ALD) among chronic alcohol abusers. Data from 4,830 people was analysed, indicating that the 10-year risk of an ALD diagnosis was 20.7% in people who were active PPI users. This compares to 16.1% in chronic alcohol users who previously used PPIs, and 12.4% for people who had never used a PPI.

“In alcohol-dependent patients, gastric acid suppression promotes the onset and progression of liver disease,” said the researchers. Although further data analysis was required on the cohort, the researchers proposed that “clinicians should consider withholding medications that suppress gastric acid, unless there is a strong medical indication” in people with alcohol-dependency.

John Smith, Chief Executive of the Proprietary Association of Great Britain, has issued a response to the study. “The researchers concluded that because of limitations in their study’s methodology, they couldn’t rule out the possibility that there could be other unidentified factors that could contribute to the link between PPIs use and liver disease. This study use data collected from mice and by reviewing a patient database,” he said.

“PPIs available over-the-counter (OTC) are intended for short-term use only and are an appropriately safe way to manage symptoms, if used in accordance with the clear on-pack instructions and the patient information leaflet inside.

Mr Smith advised people using PPIS to consult a pharmacist if symptoms do not improve after 14 days or if they have any concerns about their medicine.

Links:
C Llorente et al. ‘Gastric Acid Suppression Promotes Alcoholic Liver Disease by Inducing Overgrowth of Intestinal Enterococcus’. Published via Box app                  
PAGB response  

Clinical News

December 7 2017 LloydsPharmacy has announced a new scheme to give patients the option to receive some hospital treatments closer to home. 
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...